Comparison of cryoprotectants in hematopoietic cell infusion–related adverse events

The standard cryoprotectant for human cellular products is dimethyl sulfoxide (DMSO), which is associated with hematopoietic cell infusion‐related adverse events (HCI‐AEs) in hematopoietic stem cell transplantation including peripheral blood stem cell (PBSC) transplantation (PBSCT). DMSO is often used with hydroxyethyl starch (HES), which reduces DMSO concentration while maintaining the postthaw cell recovery. The cryoprotectant medium CP‐1 (Kyokuto Pharmaceutical Industrial) is widely used in Japan. After mixture of a product with CP‐1, DMSO and HES concentrations are 5% and 6%, respectively. However, the safety profile of CP‐1 in association with HCI‐AEs has not been investigated.

[1]  R. Hájek,et al.  Washing transplants with Sepax 2 reduces the incidence of side effects associated with autologous transplantation and increases patients' comfort , 2021, Transfusion.

[2]  Y. Kanda,et al.  Cryopreservation of Unrelated Hematopoietic Stem Cells from a Blood and Marrow Donor Bank During the COVID-19 Pandemic: A Nationwide Survey by the Japan Marrow Donor Program , 2021, Transplantation and Cellular Therapy.

[3]  Julie Meneghel,et al.  Cryopreservation as a Key Element in the Successful Delivery of Cell-Based Therapies—A Review , 2020, Frontiers in Medicine.

[4]  S. Fujiwara,et al.  Hematopoietic cell infusion‐related adverse events in pediatric/small recipients in a prospective/multicenter study , 2020, Transfusion.

[5]  T. Ikezoe,et al.  Optimal timing of apheresis for the efficient mobilization of peripheral blood progenitor cells recruited by high-dose granulocyte colony-stimulating factor in healthy donors. , 2020, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[6]  C. Hunt.  Technical Considerations in the Freezing, Low-Temperature Storage and Thawing of Stem Cells for Cellular Therapies , 2019, Transfusion Medicine and Hemotherapy.

[7]  A. Buser,et al.  The value of the post‐thaw CD34+ count with and without DMSO removal in the setting of autologous stem cell transplantation , 2019, Transfusion.

[8]  A. Hubel,et al.  Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes , 2019, Transfusion Medicine and Hemotherapy.

[9]  K. Adamik,et al.  Starch Wars—New Episodes of the Saga. Changes in Regulations on Hydroxyethyl Starch in the European Union , 2019, Front. Vet. Sci..

[10]  S. Fujiwara,et al.  Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study. , 2018, Transfusion medicine reviews.

[11]  K. Michalak,et al.  Reduction of DMSO concentration in cryopreservation mixture from 10% to 7.5% and 5% has no impact on engraftment after autologous peripheral blood stem cell transplantation: results of a prospective, randomized study , 2018, Bone Marrow Transplantation.

[12]  B. Grossman,et al.  Adverse events of cryopreserved hematopoietic stem cell infusions in adults: a single‐center observational study , 2017, Transfusion.

[13]  N. Lion,et al.  Automatic washing of thawed haematopoietic progenitor cell grafts: a preclinical evaluation , 2017, Vox sanguinis.

[14]  S. Fujiwara,et al.  Prospective randomized and crossover comparison of two apheresis machines for peripheral blood stem cell collection: a multicenter study , 2016, Transfusion.

[15]  P. Chiusolo,et al.  Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide , 2014, Transfusion.

[16]  S. Heimfeld,et al.  Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion , 2014, Bone Marrow Transplantation.

[17]  M. Kattan,et al.  Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation , 2014, Bone Marrow Transplantation.

[18]  S. Nishikawa,et al.  A Simple and Highly Effective Method for Slow-Freezing Human Pluripotent Stem Cells Using Dimethyl Sulfoxide, Hydroxyethyl Starch and Ethylene Glycol , 2014, PloS one.

[19]  D. Niederwieser,et al.  Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres , 2005, Bone Marrow Transplantation.

[20]  D. Kadidlo,et al.  Patient care during infusion of hematopoietic progenitor cells , 2004, Transfusion.

[21]  R. Navickis,et al.  A systematic review of the comparative safety of colloids. , 2004, Archives of surgery.

[22]  S. Heimfeld,et al.  A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch , 2003, Bone Marrow Transplantation.

[23]  M. Egorin,et al.  Plasma concentrations and pharmacokinetics of dimethylsulfoxide and its metabolites in patients undergoing peripheral-blood stem-cell transplants. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Akashi,et al.  A simplified method for cryopreservation of peripheral blood stem cells at -80 degrees C without rate-controlled freezing. , 1991, Bone marrow transplantation.

[25]  W. Bennett,et al.  Lack of nephrotoxicity of intravenous dimethylsulfoxide. , 1981, Clinical toxicology.